The effective threshold dose of etanercept in patients with methotrexate-resistant rheumatoid arthritis

被引:0
作者
Fangfang Chen
Yitian Lang
Shikai Geng
Xiaodong Wang
Liangjing Lu
Shuang Ye
Le Zhang
Ting Li
机构
[1] Shanghai Jiaotong University School of Medicine,Department of Rheumatology, Ren Ji Hospital
[2] Shanghai Jiaotong University School of Medicine,Department of Pharmacy, Ren Ji Hospital
[3] Shanghai Jiaotong University School of Medicine,Department of Pharmacy, Huangpu Branch, Shanghai Ninth People’s Hospital
来源
Clinical Rheumatology | 2023年 / 42卷
关键词
Cost-effectiveness; Effective cumulative dose; Etanercept; Rheumatoid arthritis; Saturated dose;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:2777 / 2786
页数:9
相关论文
共 186 条
[1]  
Welsing PM(2001)The relationship between disease activity, joint destruction, and functional capacity over the course of rheumatoid arthritis Arthritis Rheum 44 2009-2017
[2]  
van Gestel AM(1999)Long-term course and outcome of functional capacity in rheumatoid arthritis: the effect of disease activity and radiologic damage over time Arthritis Rheum 42 1854-1860
[3]  
Swinkels HL(2006)Measuring function in rheumatoid arthritis: identifying reversible and irreversible components Arthritis Rheum 54 2784-2792
[4]  
Kiemeney LA(2009)Radiographic changes in rheumatoid arthritis patients attaining different disease activity states with methotrexate monotherapy and infliximab plus methotrexate: the impacts of remission and tumour necrosis factor blockade Ann Rheum Dis 68 823-827
[5]  
van Riel PL(2014)Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2013 update of the EULAR recommendations for the management of rheumatoid arthritis Ann Rheum Dis 73 516-528
[6]  
Drossaers-Bakker KW(2011)Adverse effects of biologics: a network meta-analysis and Cochrane overview Cochrane Database Syst Rev 2 CD008794-265
[7]  
de Buck M(2015)Risk of serious infection in biological treatment of patients with rheumatoid arthritis: a systematic review and meta-analysis Lancet (London, England) 386 258-2285
[8]  
van Zeben D(2006)Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials JAMA 295 2275-565
[9]  
Zwinderman AH(2015)De-intensifying treatment in established rheumatoid arthritis (RA): Why, how, when and in whom can DMARDs be tapered? Best Pract Res Clin Rheumatol 29 550-1642
[10]  
Breedveld FC(2019)Down-titration and discontinuation strategies of tumour necrosis factor-blocking agents for rheumatoid arthritis in patients with low disease activity Cochrane Database Syst Rev 5 CD010455-535